Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96KX0
UPID:
LYZL4_HUMAN
Alternative names:
-
Alternative UPACC:
Q96KX0
Background:
Lysozyme-like protein 4, encoded by the gene with accession number Q96KX0, is implicated in the process of fertilization, as suggested by similarity to other proteins. Despite its name, it does not exhibit bacteriolytic or lysozyme activities in vitro, indicating a unique functional role distinct from traditional lysozymes.
Therapeutic significance:
Understanding the role of Lysozyme-like protein 4 could open doors to potential therapeutic strategies. Its unique function, distinct from traditional lysozyme activities, makes it a subject of interest for further research in reproductive health and beyond.